Deepak Singh

Dr. Deepak Singh

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2021 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
ANAna Rita Nobre
Ana Rita Nobre
EREmma Risson
Emma Risson
DSDeepak Singh
Deepak Singh
JMJulie S. Di Martino
Julie S. Di Martino
JCJulie F. Cheung
Julie F. Cheung
JAJulio A. Aguirre-Ghiso
Julio A. Aguirre-Ghiso

23 November 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
BKBassem D. Khalil
Bassem D. Khalil
RSRoberto Sanchez
Roberto Sanchez
TRTasrina Rahman
Tasrina Rahman
CRCarolina A Rodriguez-Tirado
Carolina A Rodriguez-Tirado
SMStefan Moritsch
Stefan Moritsch
JAJulio A. Aguirre-Ghiso
Julio A. Aguirre-Ghiso
We describe the discovery of an agonist of the nuclear receptor NR2F1 that specifically activates dormancy programs in malignant cells. The agonist led to a self-regulated increase in NR2F1 mRNA and protein and downstream transcription of a novel dormancy program. This program led to growth arrest of an HNSCC PDX line, human cell lines, and patient-derived organoids in 3D cultures and in vivo. This effect was lost when NR2F1 was knocked out by CRISPR-Cas9. RNA sequencing revealed that agonist treatment induces transcriptional changes associated with inhibition of cell cycle progression and mTOR signaling, metastasis suppression, and induction of a neural crest lineage program. In mice, agonist treatment resulted in inhibition of lung HNSCC metastasis, even after cessation of the treatment, where disseminated tumor cells displayed an NR2F1hi/p27hi/Ki-67lo/p-S6lo phenotype and remained in a dormant single-cell state. Our work provides proof of principle supporting the use of NR2F1 agonists to induce dormancy as a therapeutic strategy to prevent metastasis.

1 June 2023 in Cell Reports
Verified
Journal Article
Open access
DSDeepak Singh
Deepak Singh
SCSaul Carcamo
Saul Carcamo
EFEduardo F. Farias
Eduardo F. Farias
DHDan Hasson
Dan Hasson
WZWei Zheng
Wei Zheng
JAJulio A. Aguirre-Ghiso
Julio A. Aguirre-Ghiso
Disseminated cancer cells (DCCs) in secondary organs can remain dormant for years to decades before reactivating into overt metastasis. Microenvironmental signals leading to cancer cell chromatin remodeling and transcriptional reprogramming appear to control onset and escape from dormancy. Here, we reveal that the therapeutic combination of the DNA methylation inhibitor 5-azacytidine (AZA) and the retinoic acid receptor ligands all-trans retinoic acid (atRA) or AM80, an RARα-specific agonist, promotes stable dormancy in cancer cells. Treatment of head and neck squamous cell carcinoma (HNSCC) or breast cancer cells with AZA+atRA induces a SMAD2/3/4-dependent transcriptional program that restores transforming growth factor β (TGF-β)-signaling and anti-proliferative function. Significantly, either combination, AZA+atRA or AZA+AM80, strongly suppresses HNSCC lung metastasis formation by inducing and maintaining solitary DCCs in a SMAD4+/NR2F1+ non-proliferative state. Notably, SMAD4 knockdown is sufficient to drive resistance to AZA+atRA-induced dormancy. We conclude that therapeutic doses of AZA and RAR agonists may induce and/or maintain dormancy and significantly limit metastasis development.

2 December 2022 in Science Advances
Verified
Journal Article
Open access
DSDan Sun
Dan Sun
DSDeepak Singh
Deepak Singh
SCSaul Carcamo
Saul Carcamo
DFDan Filipescu
Dan Filipescu
BKBassem Khalil
Bassem Khalil
JAJulio A. Aguirre-Ghiso
Julio A. Aguirre-Ghiso
MacroH2A variants have been linked to inhibition of metastasis through incompletely understood mechanisms. Here, we reveal that solitary dormant disseminated cancer cells (DCCs) display increased levels of macroH2A variants in head and neck squamous cell carcinoma PDX in vivo models and patient samples compared to proliferating primary or metastatic lesions. We demonstrate that dormancy-inducing transforming growth factor–β2 and p38α/β pathways up-regulate macroH2A expression and that macroH2A variant overexpression is sufficient to induce DCC dormancy and suppress metastasis in vivo. Notably, inducible expression of the macroH2A2 variant in vivo suppresses metastasis via a reversible growth arrest of DCCs. This state does not require the dormancy-regulating transcription factors DEC2 and NR2F1; instead, transcriptomic analysis reveals that macroH2A2 overexpression inhibits cell cycle and oncogenic signaling programs, while up-regulating dormancy and senescence-associated inflammatory cytokines. We conclude that the macroH2A2-enforced dormant phenotype results from tapping into transcriptional programs of both quiescence and senescence to limit metastatic outgrowth.

Verified
Journal Article
Open access
PDF file
DSDeepak Singh
Deepak Singh
VPVaibhav Patel
Vaibhav Patel
WOWilliam Oh
William Oh
JAJulio A. Aguirre-Ghiso
Julio A. Aguirre-Ghiso
Prostate cancer has a variable clinical course, ranging from curable local disease to lethal metastatic spread. Eradicating metastatic cells is a unique challenge that is rarely met with the available therapies. Thus, targeting prostate cancer cells in earlier disease states is a crucial window of opportunity. Interestingly, cancer cells migrate from their primary site during pre-cancerous and malignant phases to seed secondary organs. These cells, known as disseminated cancer cells (DCCs), may remain dormant for months or decades before activating to form metastases. Bone marrow, a dormancy-permissive site, is the major organ for housed DCCs and eventual metastases in prostate cancer. The dynamic interplay between DCCs and the primary tumor microenvironment (TME), as well as that between DCCs and the secondary organ niche, controls the conversion between states of dormancy and activation. Here, we discuss recent discoveries that have improved our understanding of dormancy signaling and the role of the TME in modulating the epigenetic reprogramming of DCCs. We offer potential strategies to target DCCs in prostate cancer.

1 August 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
DSDeepak Singh
Deepak Singh
EFEduardo Farias
Eduardo Farias
SCSaul Carcamo
Saul Carcamo
DHDan Hasson
Dan Hasson
DSDan Sun
Dan Sun
JAJulio A. Aguirre-Ghiso
Julio A. Aguirre-Ghiso
Disseminated cancer cells (DCCs) identified in secondary organs, sometimes before the primary tumor becomes detectable and treated, can remain dormant for years to decades before manifesting. Microenvironmental and epigenetic mechanisms may control the onset and escape from dormancy, and here we reveal how a combination of the DNA methylation inhibitor 5-azacytidine (AZA) and retinoic acid receptor ligands all-trans retinoic acid (atRA), orchestrate a novel program of stable dormancy. Treatment of HNSCC tumor cells with AZA+atRA induced a SMAD2/3/4 dependent regulation of downstream transcriptional program that restored the anti-proliferative function of TGFβ signaling. Significantly, AZA+atRA or AZA+AM80, an RARα specific agonist, strongly suppresses lung metastasis formation. The metastatic suppression occurs via the induction and maintenance of phenotypically homogenous dormant SMAD4+/NR2F1+ non-proliferative DCCs. These findings suggest that strategies that maintain or induce dormancy programs may be a viable alternative strategy to improve patient outcomes by preventing or significantly delaying metastasis development.